Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 22, 2024 07:00 ET | Source: Neumora Therapeutics, Inc.

Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer

WATERTOWN, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced...
January 02, 2024 07:00 ET | Source: Neumora Therapeutics, Inc.

Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced...
December 12, 2023 07:00 ET | Source: Neumora Therapeutics, Inc.

Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer

WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced...
November 27, 2023 07:00 ET | Source: Neumora Therapeutics, Inc.

Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study

WATERTOWN, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the...
November 01, 2023 07:00 ET | Source: Neumora Therapeutics, Inc.

Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Navacaprant Phase 3 KOASTAL program in major depressive disorder on track; planned initiation of Phase 2 bipolar depression trial in 1H24 Progressing NMRA-511 and NMRA-266 toward near-term clinical...
October 30, 2023 07:00 ET | Source: Neumora Therapeutics, Inc.

Neumora Therapeutics to Participate in Upcoming Conferences in November

WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced...
October 10, 2023 07:00 ET | Source: Neumora Therapeutics, Inc.

Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development

WATERTOWN, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced...
September 14, 2023 20:49 ET | Source: Neumora Therapeutics, Inc.

Neumora Therapeutics Announces Pricing of Initial Public Offering

WATERTOWN, Mass., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (“Neumora”), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the...